Noven To Present At Lehman Brothers Global Healthcare Conference

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced that Jeffrey F. Eisenberg, its Executive Vice President and Interim Chief Executive Officer, is scheduled to provide an update on Noven’s business and prospects at the Lehman Brothers 11th Annual Global Healthcare Conference in Miami Beach on Tuesday, March 18, 2008, at 4:45 p.m. Eastern Time. Investors are invited to listen to the presentation live via webcast at www.noven.com, and a replay will be available for at least two weeks at the same site.

About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Noven’s commercialized transdermal products utilize its proprietary DOT Matrix® drug delivery technology and include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD. Oral products currently offered through the Noven marketing and sales infrastructure consist of Pexeva® (paroxetine mesylate) and Lithobid® (lithium carbonate). Developmental products in psychiatry consist of Stavzor™ (delayed release valproic acid capsule), Lithium QD (once-daily lithium carbonate), and Stavzor™ ER (extended release valproic acid capsule). The development program in women’s health consists of Mesafem™ (low-dose paroxetine mesylate), a non-hormonal product scheduled to enter Phase 3 clinical trials for vasomotor symptoms (hot flashes). See www.noven.com for additional information.

Contact:
Alina Bowman
Investor Relations Coordinator
305-253-1916